Pneumonia Research Protocols ============================ þ Intpatient Cover Letter: INCLUSION CRITERIA: - Adult patients, 18 years of age or older, with signs and symptoms consistent with bacterial pneumonia requiring intravenous antimicrobial therapy will be eligible for enrollment. - Adult patients with mild, moderate, or severe bacterial pneumonia will be eligible for enrollment. - In order to be classified as having community-acquired pneumonia, patients must have evidence of the following, defined as A, B and C: A. Fever (oral temperature >38ø C/100.4øF; rectal temperature > 39øC/102.2ø F; or tympanic membrane temperature >38.5øC/101.2ø F) and/or White Blood Cell count >12,000/mm3, or >15% immature neutrophils (bands), regardless of the peripheral WBC, or leukopenia with a total WBC count <4500/mm3 B. At least one of the following must be present: ù Productive cough ù Purulent sputum ù Dyspnea or tachypnea (respiratory rate >20 breaths per minute) ù Rigors ù Chills ù Pleuritic chest pain ù Rales and/or other evidence of pulmonary consolidation C. Radiological evidence of a new or progressive infiltrate(s) consistent with pneumonia confirmed by a radiologist's written impression or report. - Non-ventilated patients and patients requiring mechanical ventilation will be included. - Hospitalized patients (including those already admitted to an acute care facility <_ 48 hours) or outpatients (including patients under evaluation in the Emergency Department) with signs and symptoms of bacterial pneumonia will be eligible for enrollment. - Written informed consent must be obtained prior to patient enrollment. EXCLUSION CRITERIA: The following patients should be excluded from participation: - Patients with a history of allergy to carboxyquinolone derivatives or fluoronaphthyridone class quinolone derivatives - Pregnant women, nursing mothers, and women of childbearing potential in whom pregnancy cannot be excluded or who are using unreliable contraception - Nursing home residents - Patients who have been hospitalized for >48 hours at the time they develop pneumonia - Patients with moderate and severe hepatic insufficiency (Child-Pugh B and C) Patients with severe renal impairment requiring dialysis (e.g. hemodialysis, hemofiltration or CAPD) and patients with moderately severe renal impairment as determined by an historically documented (e.g., pre-therapy) creatinine clearance < 50 mL/min. - Patients with a history of tendinopathy associated with fluoroquinolones - Patients who require concomitant systemic antibacterial agents with a spectrum of antimicrobial activity similar to the study drugs - Patients who have received systemic antibacterial therapy for >24 hours prior to enrollment unless the patient is clinically failing on that therapy and the pathogen can be isolated before initiating the study drug - Patients with known prolongation of the QT interval or using Class IA (e.g. quinidine, procainamide) or Class III antiarrhythmics (e.g. amiodarone, sotalol). - Patients with uncorrected hypokalemia. - Patients with a study entry APACHE II score of >30 - Patients with a rapidly fatal underlying disease (ie, death expected within 6 months) - Patients with co-existent disease considered likely to affect the outcome of the study (e.g., lung cancer, lung abscess, collagen vascular disease affecting the lungs, cystic fibrosis, or known or suspected active tuberculosis) Patients with known bronchial obstruction or a history of post-obstructive pneumonia (this does not exclude patients with chronic obstructive pulmonary disease) - Patients who were previously enrolled in this study protocol (patients previously enrolled in BAY 12-8039 oral tablet protocols may be enrolled) - Patients who have taken an investigational drug in the last 30 days - Patients with an absolute neutrophil count <1000 cells/mm', CD4 count <200 cells/mm', or other conditions associated with significant depression in host defense. HIV testing is not mandatory - Patients with a history of a hypersensitivity reaction to multivitamin infusion (MVI) or pre-existing hypervitaminosis.